PILL250117C7000
- 0.00
- 0.000.00%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares Newsroom
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Eli Lilly to End 2024 Among Best in Big Pharma; Novo Among Worst
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
The US stock market is expected to reach new highs in 2025. How to seize the opportunity? The three most loved Index component stocks on Wall Street have been revealed!
Bank of America stated that technology giants are likely to continue outperforming the Large Cap by 2025. The bank's derivatives Analyst, Benjamin Bowler, explained that interest rate cuts and the ongoing AI boom could lead to further gains for large technology companies in the United States.
Medical stocks welcome a rebound opportunity: three major star companies may become investment highlights in 2025.
In 2024, the performance of the Medical Industry is disappointing for investors, but 2025 may bring a glimmer of hope.
Futu Morning Report | Apple hits a new high for four consecutive days! Wedbush raises the Target Price to $325; US Small Cap stocks are booming, with Drone and Quantum Computing concept stocks leading the surge.
The number of initial jobless claims in the USA fell to the lowest level in a month last week, but the duration of unemployment has increased; NVIDIA has launched the GB200 NLV4, and the GB300 is expected to be released in March next year; additional upward momentum? MicroStrategy plans to sell more shares to raise funds for purchasing Bitcoin.
Novo-Nordisk A/S faces another blow: Musk shares a weight loss photo, claiming that using Eli Lilly and Co's weight loss drug is more effective than semaglutide.
On Christmas, Musk shared a photo and called himself the Ozempic Santa Claus, clarifying that he didn't mean the drug name Ozempic for semaglutide, but rather Eli Lilly and Co's competitor Mounjaro. He also mentioned that "high doses" of Ozempic would make him fart and burp, adding that "Mounjaro seems to have fewer side effects and is more effective."
U.S. stock market close | The three major Indexes had mixed performances, with the Dow rising for five consecutive days; Drone Concept stocks surged, with SES jumping 100%; Apple continued to reach new highs, with its Market Cap approaching 4 trillion dol
After the Christmas holiday, trading is quiet. The S&P and Nasdaq briefly turned positive, with Apple reaching a new high and its Market Cap approaching 4 trillion dollars. Tesla fell by 1.8%, NVIDIA's decline narrowed, Broadcom rose over 2%, Drone concept stocks surged, the Chinese concept index rose by 0.9% at one point, Ideal Autos increased by more than 9%, and Kingsoft Cloud rose over 14%.
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Musk revealed that he switched to using Eli Lilly and Co's weight loss medication: the effect is better than Novo-Nordisk A/S's competing products, with fewer side effects.
① The world's richest man, Elon Musk, confirmed on the Social Media platform X on Wednesday that he is using Eli Lilly and Co's Mounjaro for weight loss; ② Musk revealed that he initially tried using Novo-Nordisk A/S's Ozempic for weight loss but switched to Mounjaro due to significant side effects.
10 Health Care Stocks With Whale Alerts In Today's Session
Elon Musk Says He Prefers Lilly's Mounjaro Over Novo's Ozempic
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE
Direxion Daily Pharmaceutical & Medical Bull 3X Shares Declares Quarterly Distribution of $0.0131
Pfizer (PFE.US) cancer small molecule combination therapy has received accelerated approval from the FDA.
Pfizer (PFE.US) recently announced that the USA FDA has expedited the approval of the BRAF inhibitor Braftovi (encorafenib) in combination with Erbitux (cetuximab) and the mFOLFOX6 treatment regimen (which includes fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been tested positive for the BRAF V600E mutation.
Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.
Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).
U.S. stocks closed higher | The three major Indexes collectively rose, with the Nasdaq increasing by nearly 1%; chip stocks surged, with Broadcom and Taiwan Semiconductor rising over 5%, and NVIDIA increasing nearly 4%.
① The Nasdaq China Golden Dragon Index rose by 0.91%; ② The PHLX Semiconductor Index rose by over 3%; ③ MicroStrategy purchased 5,262 Bitcoins; ④ The suspect in the UnitedHealth executive's murder case pleaded not guilty.
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Ely Lilly Shares Are Trading Higher After the FDA Approved the Company's Zepbound, a Weight Loss Drug Designed to Treat Moderate-to-severe Obstructive Sleep Apnea in Adults With Obesity.